Search Results - "Taber, David"

Immunosuppression trends in solid organ transplantation: The future of individualization, monitoring, and management by Pilch, Nicole A., Bowman, Lyndsey J., Taber, David J.

“…Immunosuppression regimens used in solid organ transplant have evolved significantly over the past 70 years in the United States. Early immunosuppression and…”
Get full text

Electronic health record-enabled routine assessment of medication adherence after solid organ transplantation: the time is now by Leino, Abbie D., Kaiser, Tiffany E., Khalil, Karen, Mansell, Holly, Taber, David J.

“…Medication nonadherence after solid organ transplantation is recognized as an important impediment to long-term graft survival. Yet, assessment of adherence is…”
Get full text

A comprehensive review of the impact of tacrolimus intrapatient variability on clinical outcomes in kidney transplantation by Gonzales, Haley M., McGillicuddy, John W., Rohan, Vinayak, Chandler, Jessica L., Nadig, Satish N., Dubay, Derek A., Taber, David J.

“…Tacrolimus (Tac) is widely used to prevent rejection and graft loss in solid organ transplantation. A limiting characteristic of Tac is the high intra and…”
Get full text

Benefits of early vascular provider involvement in wound care center management of patients with underlying arterial disease by Sundaram, Saranya, Mukherjee, Rupak, Wright, A. Sharee, Taber, David J., Visserman, Joshua, Tanious, Adam

“…Peripheral arterial disease (PAD) can reduce wound healing rates by ≤30%. Current literature suggests wound outcomes are improved when management is driven by…”
Get full text

Exploratory Analysis of the Impact of an mHealth Medication Adherence Intervention on Tacrolimus Trough Concentration Variability: Post Hoc Results of a Randomized Controlled Trial by McGillicuddy, John W., Chandler, Jessica L., Sox, Luke R., Taber, David J.

“…Background: Medication nonadherence is a leading cause of late allograft loss in kidney transplantation (KT). Tacrolimus trough coefficient of variation (CV),…”
Get full text

Effect of Angiotensin II Inhibitors on Gastrointestinal Bleeding in Patients With Left Ventricular Assist Devices by Converse, Maureen P., Sobhanian, Minoosh, Taber, David J., Houston, Brian A., Meadows, Holly B., Uber, Walter E.

“…Angiotensin II receptor activation may result in angiogenesis, and ultimately arteriovenous malformations (AVM), through transforming growth factor (TGF)-β and…”
Get full text

Long-term Assessment of NSAID Prescriptions and Potential Nephrotoxicity Risk in Adult Kidney Transplant Recipients by Chiasson, Jordan M., Fominaya, Cory E., Gebregziabher, Mulugeta, Taber, David J.

“…BACKGROUND.Nonsteroidal anti-inflammatory drug (NSAID) use is recommended to be avoided in kidney transplantation, with a paucity of studies assessing their…”
Get full text

Medication Safety Events After Acute Myocardial Infarction Among Veterans Treated at VA Versus Non-VA Hospitals by Weeda, Erin R, Ward, Ralph, Gebregziabher, Mulugeta, Axon, Robert N, Taber, David J

“…Fragmentation of health care across systems can contribute to mistakes in prescribing and filling medications among patients treated for myocardial infarction…”
Get full text

The measure of impact: Proposal of quality metrics for solid organ transplant pharmacy practice by Chandran, Mary Moss, Cohen, Elizabeth, Doligalski, Christina Teeter, Bowman, Lyndsey J., Kaiser, Tiffany E., Taber, David J.

“…As healthcare continues its transition toward value-based care, it is increasingly important for transplant pharmacists to demonstrate their impact on patient…”
Get full text

Outcome disparities between African Americans and Caucasians in contemporary kidney transplant recipients by Taber, David J, Egede, Leonard E, Baliga, Prabhakar K

“…Abstract Background Racial disparities in African-American (AA) kidney transplant have persisted for nearly 40 years, with limited data available on the scope…”
Get full text

Significant hospitalization cost savings to the payer with a pharmacist‐led mobile health intervention to improve medication safety in kidney transplant recipients by Taber, David J., Fleming, James N., Su, Zemin, Mauldin, Patrick, McGillicuddy, John W, Posadas, Aurora, Gebregziabher, Mulugeta

“…This was an economic analysis of a 12‐month, parallel arm, randomized controlled trial in adult kidney recipients 6 to 36 months posttransplant (NCT03247322)…”
Get full text

Early Assessment of National Kidney Allocation Policy Change by Rohan, Vinayak S, Pilch, Nicole, McGillicuddy, John, White, Jared, Lin, Angello, Dubay, Derek, Taber, David J, Baliga, Prabhakar K

“…The new kidney allocation changes with elimination of donor service areas (DSAs) and Organ Procurement and Transplantation Network regions were initiated to…”
Get full text

A Randomized Control Trial Testing a Medication Safety Dashboard in Veteran Transplant Recipients by Taber, David J., Milfred-LaForest, Sherry, Rife, Kelsey, Felkner, Rebecca, Cooney, Danielle, Super, Nicholas, McClelland, Samantha, Buchanan, Casey

“…Introduction Medication errors, adverse events, and nonadherence in organ transplant recipients are common and can lead to suboptimal outcomes. A medication…”
Get full text

Combining Blood Gene Expression and Cellfree DNA to Diagnose Subclinical Rejection in Kidney Transplant Recipients by Park, Sookhyeon, Guo, Kexin, Heilman, Raymond L, Poggio, Emilio D, Taber, David J, Marsh, Christopher L, Kurian, Sunil M, Kleiboeker, Steve, Weems, Juston, Holman, John, Zhao, Lihui, Sinha, Rohita, Brietigam, Susan, Rebello, Christabel, Abecassis, Michael M, Friedewald, John J

“…Subclinical acute rejection is associated with poor outcomes in kidney transplant recipients. As an alternative to surveillance biopsies, noninvasive screening…”
Get full text

Pharmacist-Led Mobile Health Intervention and Transplant Medication Safety: A Randomized Controlled Clinical Trial by Gonzales, Haley M, Fleming, James N, Gebregziabher, Mulugeta, Posadas-Salas, Maria Aurora, Su, Zemin, McGillicuddy, John W, Taber, David J

“…Medication safety events are predominant contributors to suboptimal graft outcomes in kidney transplant recipients. The goal of this study was to examine the…”
Get full text

Impact of CYP3A5 genotype on de-novo LCP tacrolimus dosing and monitoring in kidney transplantation by Rao, Nikhil, Carcella, Taylor, Patel, Neha, Bartlett, Felicia, Posadas, Maria Aurora, Casey, Michael, Dubay, Derek A., Taber, David J.

“…LCP tac has a recommended starting dose of 0.14 mg/kg/day in kidney transplant. The goal of this study was to assess the influence of CYP3A5 on perioperative…”
Get full text

Impact of CYP3A5 genotype on de-novo LCP tacrolimus dosing and monitoring in kidney transplantation by Rao, Nikhil, Carcella, Taylor, Patel, Neha, Bartlett, Felicia, Posadas, Maria Aurora, Casey, Michael, Dubay, Derek A., Taber, David J.

“…LCP tac has a recommended starting dose of 0.14 mg/kg/day in kidney transplant. The goal of this study was to assess the influence of CYP3A5 on perioperative…”
Get full text

Etiologies and Outcomes Associated With Tacrolimus Levels Out of a Typical Range That Lead to High Variability in Kidney Transplant Recipients by Taber, David J., Hirsch, Jason, Keys, Alison, Su, Zemin, McGillicuddy, John W.

“…High tacrolimus intrapatient variability (tac IPV) is associated with poor outcomes in kidney transplantation, including rejection, donor-specific antibodies,…”
Get full text

Results of a multicenter cluster-randomized controlled clinical trial testing the effectiveness of a bioinformatics-enabled pharmacist intervention in transplant recipients by Taber, David J., Ward, Ralph C., Buchanan, Casey H., Axon, Robert Neal, Milfred-LaForest, Sherry, Rife, Kelsey, Felkner, Rebecca, Cooney, Danielle, Super, Nicholas, McClelland, Samantha, McKenna, Domenica, Santa, Elizabeth, Gebregziabher, Mulugeta

“…An ambulatory medication safety dashboard was developed to identify missing labs, concerning labs, drug interactions, nonadherence, and transitions in care…”
Get full text

Multicenter, Double-Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine/Cisplatin Plus Bevacizumab or Placebo in Patients With Malignant Mesothelioma by KINDLER, Hedy L, KARRISON, Theodore G, ALBAIN, Kathy S, TABER, David A, ARMATO, Samuel G, VOGELZANG, Nicholas J, CHEN, Helen X, STADLER, Walter M, VOKES, Everett E, GANDARA, David R, LU, Charles, KRUG, Lee M, STEVENSON, James P, JÄNNE, Pasi A, QUINN, David I, KOCZYWAS, Marianna N, BRAHMER, Julie R

“…Gemcitabine plus cisplatin is active in malignant mesothelioma (MM), although single-arm phase II trials have reported variable outcomes. Vascular endothelial…”
Get full text